.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L04A_Immunosuppressants.L04AA48_Belumosudil.Belumosudil .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L04A_Immunosuppressants.L04AA48_Belumosudil.Belumosudil| name: | Belumosudil | |
| ATC code: | L04AA48 | route: | oral |
| compartments: | 1 | |
| dosage: | 200 | mg |
| volume of distribution: | 151 | L |
| clearance: | 9.83 | L/h |
| other parameters in model implementation | ||
Belumosudil is an orally administered, selective inhibitor of Rho-associated coiled-coil kinase 2 (ROCK2). It is approved for the treatment of chronic graft-versus-host disease (cGVHD) in adults and pediatric patients aged 12 years and older who have received at least two prior lines of systemic therapy.
Pharmacokinetic parameters in adult healthy volunteers and patients with cGVHD, based primarily on product labeling and limited clinical trial reports.